- Histologically confirmed liposarcoma, leiomyosarcoma, or undifferentiated/unclassified
pleomorphic sarcoma by a Dana-Farber Cancer Institute or Massachusetts General
- Participants must have measurable disease, defined as at least one lesion that can be
accurately measured in at least one dimension (longest diameter to be recorded for
non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional
techniques or as ≥10 mm with spiral CT scan, MRI, or calipers by clinical exam. See
Section 11 for the evaluation of measurable disease.
- Participants must have received at least one prior line of chemotherapy. No limit on
prior lines of therapy.
- Age ≥ 18 years.
- ECOG performance status of 0 or 1 (see Appendix A).
- Participants must have normal organ and marrow function as defined below:
- leukocytes ≥3,000/mcL
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- Hemoglobin ≥ 8 g/dL within the first 2 weeks prior to the first dose of study
drugs, transfusion is allowed.
- total bilirubin ≤1.5× institutional upper limit of normal (ULN) (except
participants with Gilbert Syndrome, who can have total bilirubin <3.0 mg/dL)
- AST(SGOT)/ALT(SGPT)<2.5 x ULN in a participant with no documented liver
metastases; ALT and AST <5.0 x ULN in a participant with documented liver
- creatinine ≤1.5× ULN OR
- creatinine clearance ≥50 mL/min/1.73 m2 for participants with creatinine levels
above institutional normal (using the Cockcroft-Gault Formula below):
- Female CrCl = (140 - age in years) x weight in kg x 0.85 72 x serum creatinine in
- Male CrCl = (140 - age in years) x weight in kg 72 x serum creatinine in mg/dL
- Available archival tumor tissue including Formalin-fixed, paraffin embedded (FFPE) or
fresh frozen, or be willing to undergo baseline biopsy for tumor tissue correlative
- The effects of eribulin and pembrolizumab on the developing human fetus are unknown.
For this reason, women of child-bearing potential (WOCBP) and men must agree to use
adequate contraception (hormonal or barrier method of birth control; abstinence) prior
to study entry and for the duration of study participation. A male participant must
agree to use a contraception as detailed in Appendix G of this protocol during the
treatment period and for at least 20 weeks, corresponding to the time needed to
eliminate any study treatments, plus an additional 120 days (a spermatogenesis cycle)
after the last dose of study treatment. A female participant is eligible to
participate if she is not pregnant (see Appendix G), not breastfeeding, and at least
one of the following conditions applies:
- Not a woman of childbearing potential (WOCBP) as defined in Appendix G OR
- A WOCBP who agrees to follow the contraceptive guidance in Appendix G during the
treatment period and for at least 20 weeks plus an additional 30 days (a
menstruation cycle) after the last dose of study treatment.
- WOCBP should use an adequate method to avoid pregnancy for at least 20 weeks plus
an additional 30 days after the last dose of investigational drug. Women of
childbearing potential must have a negative serum pregnancy test within 72 hours
prior to the start of Eribulin and Pembrolizumab. Women must not be
breastfeeding. Women who are not of childbearing potential (i.e., who are
postmenopausal or surgically sterile) do not require contraception. Women of
childbearing potential (WOCBP) is defined as any female who has experienced
menarche and who has not undergone surgical sterilization (hysterectomy or
bilateral oophorectomy) or who is not postmenopausal. Menopause is defined
clinically as 12 months of amenorrhea in a woman over 45 in the absence of other
biological or physiological causes. In addition, women under the age of 55 must
have a documented serum follicle stimulating hormone (FSH) level less than 40
- Ability to understand and the willingness to sign a written informed consent
- Participants who have had standard chemotherapy or radiotherapy within 3 weeks prior
to entering the study.
- Participants who have not recovered from adverse events (grade 2 or higher toxicities)
due to agents administered, radiotherapy, or surgery more than 3 weeks earlier, with
the exception of alopecia.
- Previous treatment with eribulin or any anti-PD-1, PD-L1, or PD-L2 agent, or with an
agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX
- Participants who are currently participating in or have participated in a study of an
investigational agent or have used an investigational device within 3 weeks prior to
the first dose of study treatment.
- Note: Participants who have entered the follow-up phase of an investigational study
may participate as long as it has been 3 weeks after the last dose of the previous
- Known brain metastases that are untreated, symptomatic or require therapy to control
symptoms. Participants with previously diagnosed brain metastases are eligible if they
have completed treatment at least 4 weeks prior to registration, are neurologically
stable and have not experienced any new neurologic symptoms for the last 4 weeks prior
to study entry, and have recovered from the effects of radiotherapy or surgery. There
must also be no requirement for immunosuppressive doses of systemic corticosteroids
(>10 mg/day prednisone equivalents) for at least 2 weeks prior to study drug
administration. Treatment for brain metastases may have included whole brain
radiotherapy, radiosurgery, surgery, or a combination as deemed appropriate by the
- Have received a live vaccine within 30 days prior to the first dose of study drug.
Examples of live vaccines include, but are not limited to, the following: measles,
mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus
Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection
are generally killed virus vaccines and are allowed; however, intranasal influenza
vaccines (eg, FluMist®) are live attenuated vaccines and are not allowed.
- Inability to comply with study and/or follow-up procedures.
- History of severe hypersensitivity reaction (≥Grade 3) to any monoclonal antibody.
- History of allergic reactions attributed to compounds of similar chemical or biologic
composition to Eribulin or Pembrolizumab.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations which in the PI's opinion makes
it undesirable for the participant to participate in the trial or which would
jeopardize compliance with the trial and study requirements.
- Pregnant women (WOCBP who had a positive serum pregnancy test on screening or 72 hours
prior to initiation of study protocol) are excluded from this study because the
effects of Eribulin and Pembrolizumab on the developing fetus are unknown. There is
the potential for teratogenic or abortifacient effects. Because there is an unknown
but potential risk for adverse events in nursing infants secondary to treatment of the
mother with Eribulin and Pembrolizumab, breastfeeding should be discontinued if the
mother is treated with Eribulin and Pembrolizumab.
- Because the effects of pembrolizumab on chronic viral infection are not well known,
participants should be excluded if they have known history of testing positive for
human immunodeficiency virus (HIV) (true positive) or known acquired immunodeficiency
syndrome (AIDS) or if they have a positive test for hepatitis B virus surface antigen
(HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or
- Participants with active autoimmune disease or history of autoimmune disease that
might recur, which may affect vital organ function or require immune suppressive
treatment including systemic corticosteroids, are excluded. These include but are not
limited to participants with a history of immune related neurologic disease such as
multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barre syndrome, or
myasthenia gravis; participants with a history of systemic autoimmune disease such as
SLE, connective tissue diseases, scleroderma, inflammatory bowel disease (IBD),
Crohn's, ulcerative colitis, or hepatitis; and participants with a history of toxic
epidermal necrolysis (TEN), Stevens-Johnson syndrome, or phospholipid syndrome. These
participants should be excluded because of the risk of recurrence or exacerbation of
disease. Participants with vitiligo or endocrine deficiencies, including thyroiditis
managed with replacement hormones such as physiologic corticosteroids, are eligible.
Participants with rheumatoid arthritis or other arthropathies; Sjögren's syndrome;
psoriasis controlled with topical medication; or participants with positive serology,
such as antinuclear antibodies (ANA) or anti-thyroid antibodies, should be evaluated
for the presence of target organ involvement and potential need for systemic treatment
but should otherwise be eligible.
- Participants are permitted to enroll if they have vitiligo, type I diabetes mellitus,
residual hypothyroidism due to autoimmune condition only requiring hormone
replacement, psoriasis not requiring systemic treatment, or conditions not expected to
recur in the absence of an external trigger (precipitating event).
- Participants should be excluded if they have a condition requiring systemic treatment
with either corticosteroids (>10 mg daily prednisone equivalents) or other
immunosuppressive medications within 14 days of study drug administration. Inhaled or
topical steroids and adrenal replacement doses <10 mg daily prednisone equivalents are
permitted in the absence of active autoimmune disease. Participants are permitted to
use topical, ocular, intraarticular, intranasal, and inhalational corticosteroids
(with minimal systemic absorption). Physiologic replacement doses of systemic
corticosteroids are permitted, even if <10 mg/day prednisone equivalents. A brief
course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for
treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction
caused by contact allergen) is permitted.
- Participants with a history of pneumonitis or interstitial lung disease.
- History of primary immunodeficiency or solid organ transplantation.
- Participants who have had evidence of active or acute diverticulitis, intra-abdominal
abscess, GI obstruction, or fistula or abdominal carcinomatosis (which are known risk
factors for bowel perforation) should be evaluated for the potential need for
additional treatment before coming on study.